摘要
阿尔茨海默病(AD)的特征在于淀粉样蛋白- β (Aβ )肽有害堆积形成老年斑,过度磷酸化tau蛋白形成神经原纤维缠结,以及大脑皮质中胆碱能突触损失。Aβ负载的斑块沉积导致小胶质细胞活化随后产生活性氧 (ROS),包括自由基。衰老的和AD神经元特别易受ROS和其他有毒刺激的侵袭。因此,减少对抗ROS的神经元的脆弱性的药物可能对AD的治疗或预防提供治疗价值。在本研究中,我们的目的是测试静脉内免疫球蛋白( IVIG)治疗是否可以在氧化损伤中维持和保护神经元。我们报道了该IVIG 治疗在原代大鼠海马神经元中保护神经元活性和突触蛋白,此外,我们证明了IVIG 疗法在原代人胎和脑混合培养物中的耐受性。事实上,高剂量(20mg/ml)的IVIG治疗能被原代人脑培养物耐受良好并表现出正常的神经细胞的表型。我们还观察到,IVIG对抗ROS介导的氧化损伤在原代人胎和脑混合培养物上有强大的神经维持作用,这些结果表明,静脉注射免疫球蛋白疗法有巨大的潜力来维持和保护原代人类神经元富集培养物且潜在地拯救受氧化损伤濒死的神经元。因此,我们的研究表明IVIG 疗法对于设计用于防止和延缓神经变性的发病以及AD病理的临床试验可能是一个重要的治疗药物。
关键词: 老化,脑,海马神经元,人类神经元,免疫球蛋白,神经保护,神经维持,神经救援,氧化应激,突触,突触蛋白
Current Alzheimer Research
Title:Intravenous Immunoglobulin Treatment Preserves and Protects Primary Rat Hippocampal Neurons and Primary Human Brain Cultures Against Oxidative Insults
Volume: 11 Issue: 7
Author(s): Debomoy K. Lahiri and Balmiki Ray
Affiliation:
关键词: 老化,脑,海马神经元,人类神经元,免疫球蛋白,神经保护,神经维持,神经救援,氧化应激,突触,突触蛋白
摘要: Alzheimer’s disease (AD) is characterized by deleterious accumulation of amyloid-β (Aβ) peptide into senile plaque, neurofibrillary tangles formed from hyperphosphorylated tau protein, and loss of cholinergic synapses in the cerebral cortex. The deposition of Aβ-loaded plaques results in microglial activation and subsequent production of reactive oxygen species (ROS), including free radicals. Neurons in aging and AD brains are particularly vulnerable to ROS and other toxic stimuli. Therefore, agents that decrease the vulnerability of neurons against ROS may provide therapeutic values for the treatment or prevention of AD. In the present study, our goal was to test whether intravenous immunoglobulin (IVIG) treatment could preserve as well as protect neurons from oxidative damage. We report that treatment with IVIG protects neuronal viability and synaptic proteins in primary rat hippocampal neurons. Further, we demonstrate the tolerability of IVIG treatment in the primary human fetal mixed brain cultures. Indeed, a high dose (20mg/ml) of IVIG treatment was well-tolerated by primary human brain cultures that exhibit a normal neuronal phenotype. We also observed a potent neuropreservatory effect of IVIG against ROS-mediated oxidative insults in these human fetal brain cultures. These results indicate that IVIG treatment has great potential to preserve and protect primary human neuronal-enriched cultures and to potentially rescue dying neurons from oxidative insults. Therefore, our findings suggest that IVIG treatment may represent an important therapeutic agent for clinical trials designed to prevent and delay the onset of neurodegeneration as well as AD pathology.
Export Options
About this article
Cite this article as:
Lahiri K. Debomoy and Ray Balmiki, Intravenous Immunoglobulin Treatment Preserves and Protects Primary Rat Hippocampal Neurons and Primary Human Brain Cultures Against Oxidative Insults, Current Alzheimer Research 2014; 11 (7) . https://dx.doi.org/10.2174/1567205011666140812113851
DOI https://dx.doi.org/10.2174/1567205011666140812113851 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Lactobacillus Rhamnosus</i> UBLR-58 and Diclofenac Potentiate the Anti- Alzheimer Activity of Curcumin in Mice
Current Enzyme Inhibition EDITORIAL [Hot Topic: Diabetes Cardiovascular Complications (Guest Editor: Costanza Emanueli)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Chaperone-like Activity of alpha-Crystallin and Other Small Heat Shock Proteins
Current Protein & Peptide Science Cellular Balance, Genes,and the Huang Ti Nei Ching Su Wen
Current Neurovascular Research PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Current Pharmaceutical Design PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry 14-3-3 Protein in CSF Reflects SIV-Mediated Pre-Synaptic Damage
Current HIV Research Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches
Current Pharmaceutical Biotechnology Treating Alzheimers Disease by Inactivating Bioactive Amyloid β Peptide
Current Alzheimer Research Is Covalently Crosslinked Aβ Responsible for Synaptotoxicity in Alzheimers Disease?
Current Alzheimer Research Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
Current Pharmaceutical Design Issues in Rehabilitation of Cognitive Deficits in Schizophrenia: A Critical Review
Current Psychiatry Reviews Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies
Current Drug Targets Conference Report: 6<sup>th</sup> Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Nov 14-16, 2013, The Westin San Diego Gaslamp Quarter Hotel, San Diego, CA, USA
CNS & Neurological Disorders - Drug Targets Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability
Current Medicinal Chemistry FDG PET/MR Imaging in Major Neurocognitive Disorders
Current Alzheimer Research Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets